No­vo Nordisk's oral semaglu­tide on par with in­jectable ver­sion in weight loss and safe­ty

An oral ver­sion of No­vo Nordisk’s semaglu­tide helped pa­tients tak­ing the high­est dose lose 15% of their body weight, the com­pa­ny re­port­ed in a new up­date.

It’s on par with No­vo’s We­govy, which is the in­jectable ver­sion of semaglu­tide that is ap­proved for weight loss. Obese or over­weight pa­tients who took We­govy lost 15% of their weight from a base­line of 105 kg, ac­cord­ing to the FDA la­bel.

In the 68-week Phase III OA­SIS-1 study, No­vo test­ed out es­ca­lat­ing dos­es up to 50 mg of semaglu­tide in over 600 pa­tients who are over­weight or obese, ac­cord­ing to da­ta re­leased at the Amer­i­can Di­a­betes As­so­ci­a­tion’s an­nu­al con­fer­ence on Sun­day night. The study found that par­tic­i­pants tak­ing the 50 mg dose saw a 15.1% body weight re­duc­tion com­pared to 2.4% on place­bo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER